IBDEI36A ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50659,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,50660,0)
 ;;=D47.3^^193^2497^64
 ;;^UTILITY(U,$J,358.3,50660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50660,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,50660,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,50660,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,50661,0)
 ;;=C82.09^^193^2497^65
 ;;^UTILITY(U,$J,358.3,50661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50661,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,50661,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,50661,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,50662,0)
 ;;=C82.00^^193^2497^66
 ;;^UTILITY(U,$J,358.3,50662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50662,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,50662,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,50662,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,50663,0)
 ;;=C82.19^^193^2497^67
 ;;^UTILITY(U,$J,358.3,50663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50663,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,50663,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,50663,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,50664,0)
 ;;=C82.10^^193^2497^68
 ;;^UTILITY(U,$J,358.3,50664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50664,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,50664,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,50664,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,50665,0)
 ;;=C82.29^^193^2497^69
 ;;^UTILITY(U,$J,358.3,50665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50665,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,50665,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,50665,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,50666,0)
 ;;=C82.20^^193^2497^70
 ;;^UTILITY(U,$J,358.3,50666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50666,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,50666,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,50666,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,50667,0)
 ;;=C82.39^^193^2497^71
 ;;^UTILITY(U,$J,358.3,50667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50667,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,50667,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,50667,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,50668,0)
 ;;=C82.30^^193^2497^72
 ;;^UTILITY(U,$J,358.3,50668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50668,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,50668,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,50668,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,50669,0)
 ;;=C82.49^^193^2497^73
 ;;^UTILITY(U,$J,358.3,50669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50669,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,50669,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,50669,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,50670,0)
 ;;=C82.40^^193^2497^74
 ;;^UTILITY(U,$J,358.3,50670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50670,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,50670,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,50670,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,50671,0)
 ;;=C82.99^^193^2497^75
 ;;^UTILITY(U,$J,358.3,50671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50671,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
